Asia Pacific Nuclear Imaging Market Research Report – Segmented By Diagnostic Technologies, Application, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 1546
Pages: 138

APAC Nuclear Imaging Market Size (2022 to 2027)

The size of the Nuclear Imaging Market in the Asia Pacific is forecasted to register a CAGR of 9.64% from 2022 to 2027. As a result, the size of the market is estimated to value USD 6.44 billion by 2027 from USD 4.07 billion in 2022.

Technological developments, expanding diagnostic applications in different diseases such as cancer and cardiovascular diseases, and the increased burden of these chronic diseases are primarily expected to drive the APAC nuclear imaging market expansion. In addition, the region's higher disease incidence raises the requirement for sophisticated technology such as nuclear imaging. These facilities are available because of a significant investment in healthcare infrastructure and medical research. In addition, these countries' per capita incomes are rising, making such technology more affordable. The Asia-Pacific nuclear imaging market has grown due to an increase in the incidence and prevalence of target conditions, advances in imaging methods employing radiopharmaceuticals, and a spike in SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) scans. Aside from data integration, there is a significant possibility to make data available via mobile technology. This allows clinicians to examine and analyze scans from any location. Companies are concentrating on developing systems with integrated technologies due to the benefits and ease of integrated systems and the high demand from doctors.

Additionally, the shift from standalone to hybrid modalities, advances in radiotracers, the growing focus on personalized medicine, investments in diagnostic imaging centers through public-private partnerships are expected to generate lucrative growth opportunities for the market to grow during the forecast period. With data integrated, imaging systems, image processing and reconstruction, computer-assisted medical condition diagnosis, 3D picture generation, and the use of appropriate quality control systems are all possible. In addition, physicians may quickly compare scans with data integration to efficiently monitor disease development. In the forecasted period, growing technical developments increased the need for trained experts, increased demand for data integrated imaging systems, and increased demand in this nation will all offer new opportunities for the nuclear imaging equipment market.

The key restraints for the APAC nuclear imaging market include increased research and development costs, the higher cost of nuclear imaging systems, and highly advanced hybrid nuclear imaging equipment. In addition, the market's growth is expected to be hampered by the short half-life of radiopharmaceuticals, supply instability, logistical challenges, and rigorous regulatory rules, as well as competition from traditional alternative diagnostic techniques. The radioactive Tc99m (technetium 99), the most widely used isotope for imaging the body in nuclear medicine scans, is now in low supply in nuclear imaging, which is one of the significant challenges to the market.

This research report on the Asia Pacific Nuclear Imaging Market has been segmented & sub-segmented into the following categories:

By Product: 

  • Standalone PET Nuclear Imaging
  • Standalone SPECT Nuclear Imaging
  • Hybrid Nuclear Imaging

By Application: 

  • Oncology
  • Cardiology
  • Neurology
  • Others

By End-User: 

  • Hospitals
  • Diagnostic Centers
  • Research Centers

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regional Analysis:

During the forecast period, the Asia Pacific area is predicted to have the greatest CAGR. The significant rise in this region can be due to rising chronic disease incidence, increased awareness of the advantages of early disease detection, and improved healthcare systems in the region. Due to the growing incidence of cancer and other chronic illnesses, increased awareness of early cancer detection, increased demand for nuclear medicine equipment, and the availability of unexplored opportunities, Asia-Pacific has significant market potential. In addition, the Asia Pacific area has the world's most populated countries, such as China and India, contributing to a significant aging population.

Among Asia-Pacific countries, India, Japan, and Australia are the substantial markets due to growing healthcare budgets and the rising popularity of several radiopharmaceuticals in numerous clinical indications.


Some of the key market participants dominating the APAC Nuclear Imaging market in this region are Mallinckrodt plc, Siemens Medical Solutions, Hitachi Medical Corporation, Medtronic Inc., General Electric Co. (healthcare division), IBA Group, Positron Corporation, Philips Medical Systems, Naviscan, Toshiba Medical Systems Corporation, Carestream Health, Lantheus Medical Imaging Inc., Cardinal Health Inc., and Bayer AG.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample